百利天恒：第三季度营收同比增长1625% 净利超6亿元扭亏为盈

Core Viewpoint - Baili Tianheng reported significant financial fluctuations in its Q3 2025 results, with a notable recovery in the third quarter after a challenging first nine months of the year [1] Financial Performance - For the period of January to September, the company achieved a revenue of 2.066 billion yuan, representing a year-on-year decline of 63.52% [1] - The net profit for the same period was -495 million yuan [1] - In Q3 alone, the company saw a remarkable revenue increase to 1.895 billion yuan, marking a year-on-year growth of 1625.08% [1] - The net profit for Q3 was 623 million yuan, indicating a turnaround from a loss of over 600 million yuan in the same quarter last year [1] Key Drivers - The revenue growth in Q3 was primarily attributed to the successful collaboration with BMS, particularly the achievement of a milestone in the global II/III phase key registration clinical trial IZABRIGHT-Breast01 on September 30 [1] - This milestone triggered the recognition of the first payment of 250 million USD under the collaboration agreement, contributing to the revenue for the period [1]